CRA consultants analyzed market power and alleged anticompetitive conduct for a CNS therapy. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing. Also considered were effects on demand resulting from the change in the form of competition upon the launch of generic products.
Merger enforcement policies of the second Trump Administration: Early developments and priorities
In the article published by the American Bar Association (ABA), “Merger Enforcement Policies of the Second Trump Administration: Early Developments and...